Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (262)	2/21/2003 10:34:47 AM
From: rkrw	Read Replies (1) \| Respond to of 824

Last update I heard was they were over 2/3rd through enrollment of 3,000 patient primo-cabg phase III. This was from Bell at the JP Morgan presentation in early January. mapdigital.com I was under the impression they were ahead of schedule. According to Bell they expect complete enrollment this half of the year. I'd think this could come very soon. Jim

To: Miljenko Zuanic who wrote (262)	2/21/2003 10:54:28 PM
From: keokalani'nui	Respond to of 824

>>time to enrollment completion is moved bit forward<< I don't think so. But only official company announcement will do. >>few other agents are also in similar PIII trials and it may effect enrollment and candidate visibility<< Recruiting patients not an issue, based on my small sample size. Anyway, since cariporide failure, is any other PIII cardio candidate seriously reaching for mortality benefit? Truth is, going to have a 3000 patient CABG PIII trial with a novel anti-inflammatory completed in about a year. Was in LA this last week. Weather was so fine!!!